Loading clinical trials...
Loading clinical trials...
A Phase 4, Randomized, Placebo-Controlled Clinical Trial of 13-valent Pneumococcal Conjugate Vaccine Efficacy in Prevention of Vaccine-Serotype Pneumococcal Community-Acquired Pneumonia and Invasive Pneumococcal Disease
The purpose of this study is to assess the efficacy of 13-valent pneumococcal conjugate vaccine in the prevention of the first episode of vaccine-type pneumococcal community-acquired pneumonia in adults.
Age
65 - No limit years
Sex
ALL
Healthy Volunteers
Yes
Pfizer Investigational Site
Tilburg, North Brabant, Netherlands
Pfizer Investigational Site
Abbekerk, Netherlands
Pfizer Investigational Site
Alkmaar, Netherlands
Pfizer Investigational Site
Alkmaar, Netherlands
Pfizer Investigational Site
Almelo, Netherlands
Pfizer Investigational Site
Almere Stad, Netherlands
Pfizer Investigational Site
Almere Stad, Netherlands
Pfizer Investigational Site
Alphen aan den Rijn, Netherlands
Pfizer Investigational Site
Amersfoort, Netherlands
Pfizer Investigational Site
Amersfoort, Netherlands
Start Date
September 1, 2008
Primary Completion Date
October 1, 2013
Completion Date
October 1, 2013
Last Updated
October 6, 2014
84,496
ACTUAL participants
VACCINE: placebo
BIOLOGICAL
VACCINE: 13-valent pneumococcal conjugate vaccine
BIOLOGICAL
Lead Sponsor
Pfizer
NCT06998251
NCT06822907
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions